



Drug/Drug Class: Butalbital Combinations Excessive Therapy Edit First Implementation Date: October 17, 2019 Revised Date: April 21, 2022 Prepared for: MO HealthNet Prepared by: MO HealthNet/Conduent Criteria Status: □ Existing Criteria □ Revision of Existing Criteria □ New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of butalbital combination products

Why Issue Selected:

Butalbital combination products are only FDA approved for the relief of the symptom complex of tension (or muscle contraction) headache. No evidence is available to support the efficacy and safety of these combination products in the treatment of multiple recurrent headaches; however, these products have long been used to treat acute migraine. These products contain butalbital mixed with a combination of caffeine, codeine, acetaminophen, and/or aspirin. Because butalbital and codeine are habit-forming and contain a potential for abuse, caution is warranted to insure proper usage. In addition, the American Migraine Prevalence and Prevention study found that use of butalbital combinations for 5 or more days per month may lead to medication overuse headaches. For these reasons, MO HealthNet will limit butalbital combination products by dosage and length of therapy.

Program-Specific Information:

Date Range FFS 10-01-2020 to 9-30-2021					
Drug	Claims	Spend	Avg Spend per Claim		
ALLZITAL (BUTALBITAL 25 MG/APAP 325 MG TAB)	0	•	i		
BUTALBITAL 50 MG/APAP 300 MG CAPSULE	0	1	-		
BUTALBITAL 50 MG/APAP 300 MG TABLET	22	\$3,933.88	\$178.81		
BUTALBITAL 50 MG/APAP 325 MG TABLET	125	\$4,508.13	\$36.06		
BUTALBITAL, APAP, & CAFFEINE 50-300-40 MG CAP	2,338	\$77,210.76	\$33.02		
BUTALBITAL, APAP, & CAFFEINE 50-325-40 MG CAP	279	\$23,966.72	\$85.90		
BUTALBITAL, APAP, & CAFFEINE 50-325-40 MG ELIX	0	-	-		
BUTALBITAL, APAP, & CAFFEINE 50-325-40 MG TAB	7,438	\$142,317.42	\$19.13		
BUTALBITAL, ASA, & CAFFEINE 50-325-40 MG CAP	232	\$8,833.67	\$38.07		
BUTALBITAL, ASA, & CAFFEINE 50-325-40 MG TAB	0	-	-		
BUTALBITAL, APAP, CAFF, & CODEINE 50-300-40-30 MG CAP	157	\$19,417.24	\$123.67		
BUTALBITAL, APAP, CAFF, & CODEINE 50-325-40-30 MG CAP	127	\$3,760.53	\$29.61		
BUTALBITAL, ASA, CAFF, & CODEINE 50-325-40-30 MG CAP	89	\$3,541.66	\$39.79		
TOTALS	10,807	\$287,490.01	\$26.60		

Type of Criteria:		□ Preferred Drug List	
	☐ Appropriate Indications	⊠ Fiscal Edit	
Data Sources:	□ Only Administrative Databases	☐ Databases + Prescriber-Supplied	

Setting & Population

- Drug class for review: Butalbital Combinations
- Age range: All appropriate MO HealthNet participants aged 12 years and older

Approval Criteria

- Claim billed is within maximum daily limits see Appendix A
- Claim billed is within maximum monthly limits see Appendix A

Denial Criteria

· Therapy will be denied if all approval criteria are not met

Laboratory Results: Progress Notes: MedWatch Form: Other: The state of the sta

Disposition of Edit

Denial: Exception code "0716" (DUR Therapy Exceeded)

Rule Type: PD

Default Approval Period

1 day

Appendix A - Butalbital combination products with maximum units per day and maximum units per month

Drug Description	Max Units Per Day	Max Units Per Month
ALLZITAL (BUTALBITAL 25 MG/APAP 325 MG TAB)	12 TABS	60 TABS
BUTALBITAL 50 MG/APAP 300 MG CAPSULE	6 CAPS	30 CAPS
BUTALBITAL 50 MG/APAP 300 MG TABLET	6 TABS	30 TABS
BUTALBITAL 50 MG/APAP 325 MG TABLET	6 TABS	30 TABS
BUTALBITAL, APAP, & CAFFEINE 50-300-40 MG CAP	6 CAPS	30 CAPS
BUTALBITAL, APAP, & CAFFEINE 50-325-40 MG CAP	6 CAPS	30 CAPS
BUTALBITAL, APAP, & CAFFEINE 50-325-40 MG ELIX	90 MLS	450 MLS
BUTALBITAL, APAP, & CAFFEINE 50-325-40 MG TAB	6 TABS	30 TABS
BUTALBITAL, ASA, & CAFFEINE 50-325-40 MG CAP	6 CAPS	30 CAPS
BUTALBITAL, ASA, & CAFFEINE 50-325-40 MG TAB	6 TABS	30 CAPS
BUTALBITAL, APAP, CAFFEINE, & CODEINE 50-300-40-30 MG CAP	6 CAPS	30 CAPS
BUTALBITAL, APAP, CAFFEINE, & CODEINE 50-325-40-30 MG CAP	6 CAPS	30 CAPS
BUTALBITAL, ASA, CAFFEINE, & CODEINE 50-325-40-30 MG CAP	6 CAPS	30 CAPS

© 2022 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

References

- Da Silva AN, Lake AE 3rd. Clinical aspects of medication overuse headaches. Headache. 2014;54(1):211-217.[PubMed 24116964]10.1111/head.12223
- Facts and Comparisons. Butalbital/Acetaminophen Oral. Accessed November 5, 2021.
- Facts and Comparisons. Butalbital/Acetaminophen/Caffeine Oral. Accessed November 5, 2021.
- Facts and Comparisons. Butalbital/Aspirin/Caffeine Oral. Accessed November 5, 2021.
- Facts and Comparisons. Butalbital/Aspirin/Caffeine/Codeine Phosphate Oral. Accessed November 5, 2021.
- Facts and Comparisons. Butalbital/Acetaminophen/Caffeine/Codeine Phosphate Oral. Accessed November 5, 2021.